【摘要】 目的 对我国已上市的6种胰高血糖素样肽-1(GLP-1)受体激动剂艾塞那肽、利拉鲁肽、利司那肽、贝那鲁肽、度拉糖肽和司美格鲁肽进行综合评价，为医疗机构提供有效的决策证据，提高卫生资源的利用质量和效率。方法 采用快速卫生技术评估(HTA)方法，计算机检索PubMed、CNKI 和维普等数据库，由 2 名评价者根据纳入和排除标准独立筛选文献、提取资料及质量评价，对上述6种药物在药学特性、有效性、安全性、经济性及其他属性五个方面进行比较，并根据《医疗机构药品评价与遴选量化记录表》进行打分。结果 司美格鲁肽最终得分为78.1分，艾塞那肽最终得分为77.0分，利拉鲁肽最终得分为76.7分，度拉糖肽最终得分为75.1分，贝那鲁肽最终得分为60.2分，利司那肽最终得分为66.7分。根据评分结果，司美格鲁肽、艾塞那肽和利拉鲁肽的综合得分较高。司美格鲁肽在降低糖化血红蛋白、空腹血糖及改善体重方面表现最为优越；其安全性评分亦位于较高水平，并显示出一定的肾脏保护作用。相比之下，艾塞那肽需每日用药，可能影响患者依从性；利拉鲁肽虽疗效较好，但日均治疗费用相对较高。司美格鲁肽采用每周一次给药方式，依从性更高，且治疗成本在同类药物中具有一定优势。结论　综合疗效、安全性、依从性及经济性等因素，司美格鲁肽或为目前我国2型糖尿病患者较为优选的GLP-1受体激动剂。更多还原

【Abstract】 Objective To conduct a comprehensive health technology assessment (HTA) of six glucagon-like peptide-1 receptor agonists (exenatide,liraglutide,lixisenatide,benaglutide,dulaglutide and semaglutide) currently approved in China,to provide evidence for decision-making in healthcare institutions and improve the quality and efficiency of healthcare resource utilization.Methods A rapid HTA approach was adopted.Literature was retrieved from PubMed,CNKI,and VIP.Two reviewers independently screened the studies,collected data,and assessed study quality based on predefined inclusion and exclusion criteria.The six drugs were compared from five dimensions,namely pharmaceutical characteristics,effectiveness,safety,cost-effectiveness,and other attributes,and were scored based on Quantitative Record Form for Drug Evaluation and Selection in Medical Institutions.Results The final scores were as follows:semaglutide 78.1;exenatide 77.0;liraglutide 76.7;dulaglutide 75.1;lixisenatide 66.7;and benaglutide 60.2.Semaglutide,exenatide,and liraglutide demonstrated higher comprehensive scores.Among them,semaglutide showed more favorable efficacy in reducing HbA1c,fasting plasma glucose,and body weight.It also ranked well in terms of safety and exhibited potential renal protective effects.While exenatide required daily administration,which may affect patient adherence.Liraglutide had good efficacy but relatively higher daily treatment costs,semaglutide’s once-weekly dosing regimen improved adherence and offered a cost advantage among its peers.Conclusion Considering efficacy,safety,adherence,and economic factors,semaglutide may become a preferred glucagon-like peptide-1 receptor agonist option for patients with type 2 diabetes in China.更多还原